The industry's claimed 'surprised' over the government's approach to the implementation, notably the 'double dipping' on statutory price reductions, appears to confront the significant challenge that it was warned of the risk last year but dismissed any concern.
The industry was warned last year but dismissed the risk of 'double dipping' on April reductions
October 10, 2022 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
The 'Dispatched' Week in Review' Podcast - 7 November
November 7, 2025 - - Podcast -
Donald Trump announces 'MFN' deals with Lilly and Novo Nordisk and end to 'global freeloading'
November 7, 2025 - - Latest News -
Sanofi employees contribute over 400 volunteer hours to community and environmental causes
November 6, 2025 - - Latest News -
Neuren posts record royalties as DAYBUE sales surpass US$100 million in third quarter
November 6, 2025 - - Australian Biotech -
US Ambassador warns UK risks losing pharma investment unless it pays more for medicines
November 6, 2025 - - Latest News -
Pfizer to continue legal fight as court rejects bid to block Novo Nordisk’s Metsera takeover bid
November 6, 2025 - - Latest News -
What next for PBS rebate system amid constitutional breaches, disputed claims, and global pressure?
November 6, 2025 - - Latest News
